Covalon Technologies : Presenting Its Latest Advanced Wound Care and Infection Control Products at Arab Health 2016

January 21st, 2016

MISSISSAUGA, Ontario January 20, 2016 - Covalon Technologies Ltd. (the 'Company' or 'Covalon') (TSXV: COV), an advanced medical technologies company, today announced it is presenting its latest line of advanced wound care and healthcare acquired infection control products from January 25-28th at the Annual Arab Health Congress in Dubai, U.A.E. Arab Health provides an opportunity for Covalon to meet the 65,000 medical and scientific community attendees, medical product manufacturers, wholesalers and distributors from the Middle East, Asia, Europe, North America and most other regions of the world.

Covalon will be showcasing its category transforming products at Arab Health, including SurgiClear™ and IV Clear™ - breathable, clear, dual antimicrobial silicone adhesive surgical wound and vascular access securement dressings, as well as ColActive Plus Ag, a patented BioMatrix wound dressing available for use in most Middle Eastern jurisdictions.

'With this being our 5 year at the Arab Health Congress, we have shown not only our commitment to launching innovations into the region, but the region has shown us in return its willingness to be leaders in the adoption of new medical technologies that address its biggest healthcare challenges.' said John Hands, Covalon's Senior Director of Global Marketing. 'After rigorous evaluations by leading physicians and clinicians in Saudi Arabia, Qatar, Kuwait, UAE, Bahrain, Oman and other countries, our products have been successful in winning business in no less than 14 tenders this past year alone. Covalon and our brands are becoming market leaders in the Middle East as a result of the hard work of our partners in the region, like Cure Development International Ltd.'

'We are pleased to represent Covalon and their portfolio of world-class products in the Gulf Cooperation Council ('GCC') countries', said Azzam Al Sulaim, Cure Development International, Ltd.'s Chief Executive Officer. 'The combination of our highly experienced clinical sales experts and Covalon's life-saving products is providing needed advanced wound care, infection control and surgical dressing solutions to the GCC that are having a positive impact on clinicians and their patients. We look forward to introducing more of Covalon's products to the GCC as they become available.'

To learn more about Covalon's products and services, please visit us at booth Hall 1C18 in the Dubai World Trade Centre from January 25 to 28 or contact Brian Pedlar, CEO Covalon Technologies Ltd. at [e-mail].

To learn more about Covalon, please contact:

Brian Pedlar, CEO, Covalon Technologies Ltd.

Email: [e-mail]

Phone: [phone] x 233

Toll free: 1.877.711.6055

Web site: www.covalon.com

Twitter: @covalon

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan, 'estimate', 'expect', 'intend' and statements that an event or result 'may', 'will', 'should', 'could' or 'might' occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Click here to download the associated PDF